Loading...

VNDA VANDA PHARMACEUTICALS INC US FDA Inspections 8-K Filing

VND

VND

VANDA PHARMACEUTICALS INC

(VNDA)

2025 8-K

FDA Approval Update

Regulatory Update

Earnings Update

FDA Collaboration Reached

Financial Statements

Financial Statements

FDA Application Update

Executive Compensation

Earnings Results

New Drug Application

Earnings Announcement

Acquisition Proposal

Bylaw Amendments

Tradipitant Update

Amendment to Rights Agreement

Rejection of Acquisition Pr...

Acquisition Proposal

Indication of Interest

Rejection of Acquisition Pr...

Management Changes

Annual Meeting of Stockholders

Acquisition Proposal

Dividend Distribution

FDA Response Letter

Compensation Committee Awar...

Amendment to Form 8-K/A

FDA Update on Insomnia Trea...

Bylaws Amendment

Acquisition of PONVORY Rights

Denial of Rehearing

Annual Meeting Voting Results

Appointment of Director

Regulation FD Disclosure

Compensation Committee Awar...

External Links:

On March 14, 2025, Vanda Pharmaceuticals announced that the FDA accepted its new drug application for tradipitant for motion sickness, with a decision expected by December 30, 2025; the drug showed significant efficacy in trials, reducing vomiting rates compared to placebo.

AI Assistant

VANDA PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.